Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relevance of Spike/Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2.
Barbieri SS, Cattani F, Sandrini L, Grillo MM, Amendola A, Valente C, Talarico C, Iaconis D, Turacchio G, Lucariello M, Lione L, Salvatori E, Amadio P, Garoffolo G, Maffei M, Galli F, Beccari AR, Sberna G, Marra E, Zoppi M, Michaelides M, Roscilli G, Aurisicchio L, Bertini R, Allegretti M, Pesce M. Barbieri SS, et al. Among authors: allegretti m. Signal Transduct Target Ther. 2023 May 19;8(1):203. doi: 10.1038/s41392-023-01488-3. Signal Transduct Target Ther. 2023. PMID: 37208343 Free PMC article. No abstract available.
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.
Cassano M, Biressi S, Finan A, Benedetti L, Omes C, Boratto R, Martin F, Allegretti M, Broccoli V, Cusella De Angelis G, Comoglio PM, Basilico C, Torrente Y, Michieli P, Cossu G, Sampaolesi M. Cassano M, et al. Among authors: allegretti m. PLoS One. 2008 Sep 16;3(9):e3223. doi: 10.1371/journal.pone.0003223. PLoS One. 2008. PMID: 18795097 Free PMC article.
Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.
Brandolini L, Cristiano L, Fidoamore A, De Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque B, Benedetti E, Ruffini PA, Cifone MG, Giordano A, Alecci M, Allegretti M, Cimini A. Brandolini L, et al. Among authors: allegretti m. Oncotarget. 2015 Dec 22;6(41):43375-94. doi: 10.18632/oncotarget.6234. Oncotarget. 2015. PMID: 26517518 Free PMC article.
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, Sordi V, Magistretti P, Daffonchio L, Ruffini PA, Allegretti M, Secchi A, Bonifacio E, Piemonti L. Citro A, et al. Among authors: allegretti m. J Clin Invest. 2012 Oct;122(10):3647-51. doi: 10.1172/JCI63089. Epub 2012 Sep 17. J Clin Invest. 2012. PMID: 22996693 Free PMC article. Clinical Trial.
Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R. Pflugfelder SC, et al. Among authors: allegretti m. Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26. Ophthalmology. 2020. PMID: 31585826 Free article. Clinical Trial.
The IL-8-CXCR1/2 axis contributes to diabetic kidney disease.
Loretelli C, Rocchio F, D'Addio F, Ben Nasr M, Castillo-Leon E, Dellepiane S, Vergani A, Abdelsalam A, Assi E, Maestroni A, Usuelli V, Bassi R, Pastore I, Yang J, El Essawy B, Elased KM, Fadini GP, Ippolito E, Seelam AJ, Pezzolesi M, Corradi D, Zuccotti GV, Gallieni M, Allegretti M, Niewczas MA, Fiorina P. Loretelli C, et al. Among authors: allegretti m. Metabolism. 2021 Aug;121:154804. doi: 10.1016/j.metabol.2021.154804. Epub 2021 Jun 10. Metabolism. 2021. PMID: 34097917
BCAAs and Di-Alanine supplementation in the prevention of skeletal muscle atrophy: preclinical evaluation in a murine model of hind limb unloading.
Mantuano P, Boccanegra B, Bianchini G, Conte E, De Bellis M, Sanarica F, Camerino GM, Pierno S, Cappellari O, Allegretti M, Aramini A, De Luca A. Mantuano P, et al. Among authors: allegretti m. Pharmacol Res. 2021 Sep;171:105798. doi: 10.1016/j.phrs.2021.105798. Epub 2021 Aug 2. Pharmacol Res. 2021. PMID: 34352400
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Piemonti L, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, Pozzilli P, Giorgino F, Cossu E, Daffonchio L, Goisis G, Ruffini PA, Maurizi AR, Mantelli F, Allegretti M. Piemonti L, et al. Among authors: allegretti m. Diabetes Obes Metab. 2022 Sep;24(9):1840-1849. doi: 10.1111/dom.14770. Epub 2022 Jul 4. Diabetes Obes Metab. 2022. PMID: 35589610 Free PMC article. Clinical Trial.
172 results